Mechanistic considerations for the use of monoclonal antibodies for cancer therapy
Since the approval of rituximab in 1997, monoclonal antibodies (mAbs) have become an increasingly important component of therapeutic regimens in oncology. The success of mAbs as a therapeutic class is a result of great strides that have been made in molecular biology and in biotechnology over the pa...
| الحاوية / القاعدة: | Cancer Biology & Medicine |
|---|---|
| المؤلفون الرئيسيون: | , |
| التنسيق: | مقال |
| اللغة: | الإنجليزية |
| منشور في: |
China Anti-Cancer Association
2014-03-01
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://www.cancerbiomed.org/index.php/cocr/article/view/630 |